CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs specifically designed to address limitations of current therapies in selected established markets.  We have developed a broad portfolio of 12 product candidates utilizing our drug formulation technology using Captisol^® cyclodextrins.  Captisol cyclodextrins are a patent protected, specifically modified family of cyclodextrins designed to improve solubility, stability, bioavailability, safety and/or dosing of a number of active pharmaceutical ingredients, or APIs. By applying our Captisol technology to APIs with known safety and efficacy characteristics, we believe that we can create differentiated products with significant commercial opportunities, while simultaneously reducing development risk, costs and timelines as compared to the development of new chemical entities.

CAPTISOL and Captisol-Enabled are registered trademarks of CyDex Pharmaceuticals, Inc.